Cargando…
Current Regulatory Requirements for Biosimilars in Six Member Countries of BRICS-TM: Challenges and Opportunities
Background: The aim of the study was to identify, interpret, and compare the current perspectives of regulatory agencies in six member countries of BRICS-TM (Brazil, Russia, India, China, South Africa, Turkey, and Mexico) on the different criteria used for biosimilar development and marketing author...
Autores principales: | Rahalkar, Hasumati, Sheppard, Alan, Santos, Gustavo Mendes Lima, Dasgupta, Chitralekha, Perez-Tapia, Sonia Mayra, Lopez-Morales, Carlos A., Salek, Sam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458962/ https://www.ncbi.nlm.nih.gov/pubmed/34568384 http://dx.doi.org/10.3389/fmed.2021.726660 |
Ejemplares similares
-
Comparison of BRICS-TM Countries' Biosimilar Regulatory Frameworks With Australia, Canada and Switzerland: Benchmarking Best Practices
por: Rahalkar, Hasumati, et al.
Publicado: (2021) -
Challenges Faced by the Biopharmaceutical Industry in the Development and Marketing Authorization of Biosimilar Medicines in BRICS-TM Countries: An Exploratory Study
por: Rahalkar, Hasumati, et al.
Publicado: (2021) -
Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines
por: Rahalkar, Hasumati, et al.
Publicado: (2018) -
BRICS nations and the opportunities for community physical activity interventions
por: Garber, Carol Ewing
Publicado: (2019) -
How has formal institutions influenced opportunity and necessity entrepreneurship? The case of brics economies
por: Udimal, Thomas Bilaliib, et al.
Publicado: (2020)